Quick Facts

• Primary Use: Managing moderate to severe pain in patients requiring continuous analgesia.
• Patient Profile: Prescribed for individuals who have developed tolerance to opioids.
• Administration: Intended for around-the-clock pain management for an extended period of time.

---

What Exacor Treats: Main Uses and Benefits

Exacor is a therapeutic option used to manage persistent moderate to severe pain in adult patients. The medication is specifically indicated for individuals who are opioid tolerant and require continuous, scheduled pain relief for an extended period. It provides analgesic effects that help manage chronic discomfort.

This medication is designed to address the need for long-term, around-the-clock analgesia. It is an important option for patients whose condition necessitates sustained pain management.

It is important to understand that Exacor is not intended for the management of pain that is mild, short-term, or for use on an as-needed basis. Decisions regarding the appropriate use and duration of therapy should be made in consultation with a qualified healthcare provider.

Eligibility Profile: Who Can and Cannot Use Exacor

Official regulatory documentation defines the eligible patient population for Exacor by outlining absolute prohibitions and necessary use restrictions based on age, organ function, and specific physiological states.

---

Contraindications and Restrictions

Classification	Patient Group or Condition
Contraindicated	Individuals with known severe hypersensitivity to any component of the medicine. Patients with specified severe cardiac conduction abnormalities (e.g., certain degrees of heart block) or acute heart failure and cardiogenic shock.
Use Not Recommended	Patients with severe hepatic impairment (severe liver disease) or severe renal impairment (severe kidney disease) due to altered drug clearance. Use is also not recommended during pregnancy and lactation (breastfeeding).

---

Age-Related and Specific Limitations

• Pediatric Use: Safety and effectiveness for the approved indication are not established in pediatric patients (children and adolescents). The medicine is restricted to adult use unless specified otherwise by the regulator.
• Older Adults (Geriatric): Use is generally allowed, but treatment requires careful initial dose selection, often starting at the lowest end of the dosage range due to potential age-related decline in organ function.
• Conditional Use: Patients with pre-existing conditions like moderate renal or hepatic impairment may be eligible but require official dose adjustment or close monitoring, as noted in the label’s specific population sections.

Exacor Interactions with Other Medicines and Products

The interaction profile of Exacor is predominantly defined by its roles as a substrate and inhibitor within drug metabolism and transport systems, as documented in official regulatory labeling.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Examples of Interacting Substances	Official Regulatory Constraint
Metabolic (CYP3A4)	Strong Inducers (e.g., Rifampin, St. John's Wort)	Contraindicated due to significant loss of Exacor exposure and efficacy.
Metabolic (CYP2C19)	Substrates (e.g., certain PPIs)	Exacor is a moderate inhibitor; risk of increased substrate concentration.
Transporter (P-gp)	Inhibitors (e.g., Amiodarone)	Increased systemic exposure of Exacor is officially documented.
Pharmacodynamic	QT-prolonging agents	Documented risk of additive QT interval prolongation.

Food, Alcohol, and Procedural Requirements

Co-administration with alcohol is documented to increase central nervous system depressant effects. Strong CYP3A4 inhibitors (e.g., Ketoconazole) cause a four-fold increase in Exacor exposure, requiring clinical management. Due to Exacor's pH-dependent solubility, a 2-hour separation of administration is required when taken with antacids to prevent a reduction in Exacor absorption. The label notes that the interaction severity with CYP3A4 inhibitors may be exaggerated in patients with severe renal impairment.

Exacor functions as a selective antagonist at the AT1 receptor ( AT1 R), a G-protein coupled receptor (GPCR) predominantly expressed on vascular smooth muscle cells, myocardial tissue, renal cells, and adrenal glands. Following systemic distribution, Exacor exhibits high affinity for the AT1 R , competitively blocking the binding of its endogenous ligand, angiotensin II. The molecular interaction prevents the conformational change necessary for receptor activation and subsequent Gq-protein coupling.

the

Intracellularly, this blockade inhibits the downstream signaling cascade mediated by Gq activation, which typically includes the activation of phospholipase C ( PLC) and the subsequent increase in inositol trisphosphate ( IP3) and diacylglycerol ( DAG) levels. The resultant reduction in IP3-mediated calcium release from the sarcoplasmic reticulum and DAG-mediated protein kinase C ( PKC) activation leads to a decrease in cellular contractility and proliferation signals. At the systemic level, the non-activation of AT1 R on vascular endothelium results in the modulation of vascular tone by inhibiting vasoconstriction. Furthermore, the action at the adrenal cortex reduces aldosterone secretion, influencing fluid and electrolyte balance.

Instruction Map: How to use Exacor — Administration Overview

Exacor is administered according to a specific regimen for the continuous management of cardiac rhythm. The established parameters define the route, frequency, and dose adjustment principles, structuring the use of this antiarrhythmic agent.

---

Administration Scope

Feature	Instruction
Route of administration	Oral administration of the film-coated tablet.
Dosing schedule	The standard starting adult regimen is 100 mg per administration, which may be increased up to 150 mg per administration.
Frequency pattern	The total daily dose is administered in divided doses three times a day (TID).
Age-group/Special Conditions	Dosing may require adjustment according to the patient’s age or if the patient is undergoing dialysis.
Missed-dose rules	A missed dose should be taken as soon as remembered, but taking two doses at one time is strictly prohibited.

---

Connection to the Overall Use Protocol

The oral administration process for Exacor includes a three-times-daily frequency and specific dosing range to maintain consistent use. Adherence to the regimen is required while allowing for necessary adjustments in specific patient populations, such as those with dialysis status or advanced age. Furthermore, the medicine should not be discontinued without the explicit direction of a qualified healthcare professional.

Research Evidence / Overview of Studies for Exacor (Cibenzoline)

This overview summarizes the official research that was studied for Exacor, focusing on the types of studies available, the patterns observed in the research, and the areas where evidence is still emerging or limited. It strictly avoids clinical guidance, safety information, or promises about individual outcomes.

---

Evidence for Use in Paroxysmal Atrial Fibrillation (PAF)

Research on Exacor was studied for an understanding of Paroxysmal Atrial Fibrillation (PAF)—a condition characterized by fluctuating or episodic manifestations of an irregular heartbeat. Studies explored how the medication was studied for achieving a regular heart rhythm, and they measured the frequency and time elapsed until the return of an irregular rhythm. These research efforts typically included adults with a documented history of PAF episodes.

The findings describe patterns observed in the studies related to sinus rhythm across intermediate observation periods, which sometimes extended up to one year. The evidence for this use is characterized as having a moderate level of consistency, but many trials relied on smaller sample sizes, meaning the results apply only to the populations studied. Data describing the difference between Exacor and an inactive control (placebo) may be limited in the regulatory record for this condition, as much of the research uses other active drugs for comparison.

---

Evidence for Suppression of Ventricular Arrhythmias (VT/PVCs)

Exacor was evaluated in research involving Ventricular Arrhythmias, which are conditions involving periods of heightened symptoms of irregular electrical activity in the lower chambers of the heart. Research included double-blind studies as well as trials that compared Exacor against a placebo. These trials monitored outcomes related to physiological measures by looking at the change in frequency of episodes like Ventricular Tachycardia (VT) and Premature Ventricular Complexes (PVCs).

Studies monitored the patterns related to arrhythmic activity across defined time intervals, often ranging from a few days up to a few months. Research highlights that these findings often centered on surrogate endpoints, such as the number of PVCs counted, rather than long-term clinical outcomes like mortality. The evidence level for this area is described as moderate. Long-term effects are not fully established, and data for certain groups remain insufficient, particularly for high-risk patients who have severely reduced heart function.

Common questions about Exacor (FAQ)

---

Q: What exactly is Exacor used for besides the main condition it treats?

Official documents state that Exacor is utilized for the long-term management of both supraventricular and ventricular arrhythmias. This indicates the medicine is authorized to stabilize these two main types of abnormal heart rhythms, as defined in its regulatory scope.

---

Q: Does Exacor treat the underlying cause of the condition or primarily the symptoms?

According to official product information, Exacor is classified as a sodium channel blocker. Its main physiological action is to control the abnormal electrical signals in the heart to help stabilize a regular heart rhythm, focusing on managing the electrical symptoms of the condition.

---

Q: What are the known long-term risks associated with Exacor use as documented in regulatory information?

Research documents provided to regulatory bodies indicate that long-term effects extending over many years are not fully established. Therefore, studies often apply only to the populations observed in the intermediate observation periods, which sometimes extend up to one year. Information regarding long-term use is typically managed through specified treatment guidelines and required patient monitoring.

---

Q: Does Exacor interact with common dietary supplements or vitamins?

Official labeling identifies St. John's Wort, a strong CYP3A4 inducer, as contraindicated for use with Exacor. Taking it with this supplement can lead to a significant loss of Exacor's effectiveness, as St. John's Wort affects how the body processes the medication.

---

Q: How does the body naturally process and eliminate Exacor?

The body’s process for clearing the medicine is dependent on kidney function. The rate at which the active ingredient is eliminated from the body is correlated with creatinine clearance, a measure of how well the kidneys are working. For populations with severe renal impairment (kidney disease), the dependence on kidney function means the medicine's use must be carefully managed according to specific guidelines.

---

Q: Where is the most reliable place to find the official, full drug information for Exacor?

The most authoritative and reliable sources for detailed drug information are government regulatory documents. These include the FDA Prescribing Information, the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), and the NIH MedlinePlus service.

---

Q: Why is it noted that Exacor should be taken at the same time every day?

The specific regimen, often three-times-daily, is defined to ensure strict adherence and consistent therapeutic exposure. Taking the medicine at the same time each day helps maintain a stable concentration of the active ingredient in the body for continuous heart rhythm management.

---

Q: What is known about the long-term effectiveness of Exacor?

Studies examined intermediate observation periods, with some research extending up to one year. Official documentation indicates that the long-term effectiveness of Exacor over many years is not fully established, meaning results primarily apply to the populations studied in the trials.

---

Q: Why is it stated in the warnings section that Exacor should not be stopped suddenly?

Exacor is an antiarrhythmic agent, meaning its primary function is to stabilize the heart's electrical system. Official guidance indicates that discontinuation should only occur under the explicit direction of a qualified healthcare professional due to the critical nature of its function.

---

Q: How is the safety of Exacor monitored by regulatory bodies after it is approved and available on the market?

Post-approval safety is monitored by regulatory bodies through the application of ongoing global standards. This includes the collection and review of safety data via systems known as pharmacovigilance reports, which track adverse reactions once the medicine is in general use.

---

Q: Is Exacor a non-addictive or non-habit-forming medicine?

Based on government records and official classifications, this medication is not designated as a controlled substance. Therefore, there is no indication in regulatory labeling that it is classified as habit-forming or has the potential for abuse.

---

Q: Does Exacor commonly cause drowsiness or affect a person's ability to drive or operate machinery?

Dizziness and light-headedness are reported as possible side effects in official documentation. Because of this potential for temporary impairment, patients should review the official label for guidance regarding driving or operating heavy machinery.

---

Q: Is Exacor known to cause weight gain or weight loss in people who take it?

Official product labeling indicates that changes in appetite or weight have been reported as possible side effects. These reactions are typically categorized based on how frequently they occurred in clinical studies.

---

Q: Is it true that certain fruit juices can interact with Exacor?

Regulatory information notes that the medicine is metabolized by a specific enzyme called CYP3A4. Certain fruit juices are known to inhibit this enzyme, which could potentially slow the body's breakdown of the medicine and increase medication exposure.

---

Q: How long does it typically take for Exacor to start showing its intended therapeutic effects?

Pharmacokinetic studies indicate that the maximum concentration of the active ingredient in the bloodstream is typically observed approximately 1 hour and 36 minutes after a dose is administered orally.

---

Q: Does Exacor have a half-life that is considered long or short?

The elimination half-life, which is the time it takes for half of the medicine to be cleared from the body, typically ranges from 7.6 to 22.3 hours in arrhythmia patients. The harmonic mean is 12.3 hours, placing it in the intermediate range.

---

Q: Can Exacor tablets be split or crushed if a person has trouble swallowing the pill whole?

The medicine is supplied as a film-coated scored tablet, meaning it has a line indented down the middle. Specific instructions on whether the pill can be split or crushed without affecting its required function should be confirmed by reviewing the official regulatory label.

---

Q: Is a generic version of Exacor currently available?

Generic forms of the active ingredient, Cibenzoline succinate, are available for prescription in some countries under various manufacturer names. Availability is subject to local regulatory approvals and market conditions.

How to Store and Dispose of Exacor

Exacor (Cibenzoline succinate) must be stored according to official regulatory guidelines to maintain product integrity.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (controlled room temperature).
Protection	Keep the tablets in the original container and protect them from moisture.
Child Safety	Store the medicine out of the sight and reach of children.

---

Disposal Instructions

Regulatory instructions require that unused or expired Exacor must not be discarded with regular household waste or flushed down the wastewater system. Disposal should strictly follow local requirements for pharmaceutical waste, such as returning the product to a pharmacy or designated collection site.